Compare TSLX & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | ANIP |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2014 | N/A |
| Metric | TSLX | ANIP |
|---|---|---|
| Price | $21.65 | $79.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 6 |
| Target Price | $23.50 | ★ $105.83 |
| AVG Volume (30 Days) | ★ 475.7K | 404.2K |
| Earning Date | 02-12-2026 | 02-27-2026 |
| Dividend Yield | ★ 9.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.04 | 1.67 |
| Revenue | $464,512,000.00 | ★ $826,880,000.00 |
| Revenue This Year | N/A | $44.06 |
| Revenue Next Year | N/A | $9.06 |
| P/E Ratio | ★ $10.38 | $47.45 |
| Revenue Growth | N/A | ★ 48.87 |
| 52 Week Low | $18.58 | $52.74 |
| 52 Week High | $25.17 | $99.50 |
| Indicator | TSLX | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 48.17 |
| Support Level | $21.11 | $76.69 |
| Resistance Level | $22.16 | $80.29 |
| Average True Range (ATR) | 0.37 | 2.45 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 61.91 | 54.41 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.